- National multimedia campaign, “I’m a PanOptimist,” focuses
on the renewed optimism of having complete vision after cataract
surgery
- Ladd to share her journey receiving the first and only
trifocal cataract replacement lens in the U.S. — AcrySof® IQ
PanOptix®
- More than 25 million Americans are affected by cataracts,1
which cause dull, blurry vision and can have an emotional impact
for many
Regulatory News:
Alcon (SIX: ALC) (NYSE: ALC), the global leader in eye care,
today announced a partnership with actress Cheryl Ladd, best known
from the iconic hit TV series Charlie’s Angels, who recently
underwent cataract surgery and received the AcrySof® IQ PanOptix®
Lens. Cheryl will be sharing her story through a national campaign
— “I’m a PanOptimist” — and hopes to inspire people with cataracts,
the most common age-related eye condition,2 to take charge of their
diagnosis, understand their treatment options and reclaim their
optimism for life in all its color.
Cataracts, a cloudiness of the natural lens of the eye that can
impair vision, are treated by replacing the lens with an
intraocular lens (IOL). PanOptix — the first and only trifocal IOL
available in the U.S. — corrects and sharpens vision at near,
intermediate and distance so patients wear glasses less often.3,4
PanOptix is designed for today’s active lifestyles, from viewing
mobile devices and computer screens to high-quality distance vision
in a range of lighting conditions.
“When you are first diagnosed with cataracts, it’s easy to
accept that having worse vision is just a natural part of aging —
or that wearing glasses and seeing colors fade is all normal,” said
Ladd. “For me, surgery was an opportunity to take action so that I
could improve my vision and continue to live an active life.
Choosing the PanOptix lens has enabled me to see more like I did
when I was younger. Now I’m optimistic — a PanOptimist — about life
after cataract surgery.”
More than 25 million Americans suffer from cataracts. That
number is poised to jump to 38.5 million by 2032 and to 45.6
million by 2050.1 Studies have shown that because cataracts can
make simple, day-to-day tasks harder, many feel annoyed, frustrated
and old. However, cataract surgery does have emotional benefits,
with patients reporting being happier and more satisfied
post-surgery.5
“The response we’ve received from surgeons and patients since we
launched PanOptix in the U.S. has been overwhelmingly positive,”
said Sergio Duplan, Region President for Alcon North America. “This
lens is the latest advancement from the AcrySof family of lenses —
the most implanted cataract replacement lenses worldwide.6 When we
heard Cheryl was receiving this lens, we knew other patients would
benefit from hearing her PanOptimist story. Our hope is that her
story inspires others to speak with their eye doctor about their
lens options and choose one that best suits their lifestyle
needs.”
More than ninety-nine percent of PanOptix patients in the FDA
clinical study said they would choose the same lens again, and
ninety-eight percent of people with the PanOptix Lens would
recommend it to family and friends.3
To learn more about PanOptix and the campaign, please visit
mycataracts.com or follow us @MyCataractJourneybyAlcon on Facebook.
Join in on the social conversation using #PanOptimist.
About Cataracts
A cataract is a cloudy area in the natural lens of the eye that
affects vision. As a cataract develops, the eye’s lens gradually
becomes hard and cloudy allowing less light to pass through, which
makes it more difficult to see. The vast majority of cataracts
result from normal aging, but radiation exposure, taking steroids,
diabetes and eye trauma can accelerate their development.7
Cataracts are the most common age-related eye condition and the
leading cause of preventable blindness.2 More than twenty-five
million people in the U.S. have cataracts.1 Cataracts are treated
by removing the eye’s cloudy natural lens and surgically replacing
it with an intraocular lens or IOL. More than ninety-eight percent
of cataract surgeries are considered successful, and patients
typically can return to their normal routines within 24 hours.8
About PanOptix
The AcrySof IQ PanOptix Trifocal IOL is a type of multifocal IOL
used to focus images clearly onto the back of your eye (retina) to
allow clear vision after the cataract removal. In addition, the
center of the AcrySof IQ PanOptix Trifocal IOL allows for better
near (reading) vision and intermediate (computer work) vision
versus what a monofocal lens would provide.
Potential Side Effects: Due to the design of multifocal IOLs,
there are some side effects that can be associated with the AcrySof
IQ PanOptix Trifocal IOL models. These may be worse than with a
monofocal IOL, including visual disturbances such as glare, rings
around lights, starbursts (rays around light sources), and reduced
contrast sensitivity (decrease in ability to distinguish objects
from their background, especially in dim lighting). These side
effects may make it more difficult to see while driving at night or
completing tasks in low lighting conditions such as at night or in
fog, or in a dimly lit room after surgery as compared to before
surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
Disclaimer
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
References
- Prevent Blindness, Millions of Americans Have Cataract.
Accessed March 5, 2020. Available at
https://www.preventblindness.org/millions-americans-have-cataract.
- Centers for Disease Control and Prevention, Vision Health
Initiative. Accessed March 5, 2020. Available at:
https://www.cdc.gov/visionhealth/basics/ced/index.htm.
- AcrySof® IQ PanOptix® Directions For Use.
- Compared to AcrySof® monofocal IOL.
- New Alcon survey reveals that people are happier, more
satisfied with their lives after cataract surgery [news release].
Fort Worth, TX: Alcon Laboratories, Inc; June 1, 2017. Available at
https://www.alcon.com/media-release/new-alcon-survey-reveals-people-are-happier-more-satisfied-their-lives-after-cataract.
Accessed March 5, 2020.
- Alcon flagship AcrySof intraocular lens reaches 100 million
implants and counting [news release]. Fort Worth, TX: Alcon
Laboratories, Inc; September 29, 2017. Available at
https://www.alcon.com/media-release/alcon-flagship-acrysofr-intraocular-lens-reaches-100-million-implants-and-counting.
Accessed March 5, 2020.
- National Institutes of Health (NIH), National Eye Institute
(NEI), Causes of Cataract. Accessed March 5, 2020. Available at:
https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/cataracts/causes-cataract.
- Cleveland Clinic, Cataracts. Accessed March 5, 2020. Available
at:
https://my.clevelandclinic.org/health/diseases/8589-cataracts.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Connect with us on
Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200311005165/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Blake Overby
+ 1 817 551 4328 (Office) + 1 682 321 2897 (Mobile)
blake.overby@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From May 2024 to Jun 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2023 to Jun 2024